Results 221 to 230 of about 7,562,928 (333)

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

International Publication Trends of Studies Comparing Total Ankle Arthroplasty and Ankle Arthrodesis: A Systematic Literature Review. [PDF]

J Am Acad Orthop Surg Glob Res Rev
Randsborg PH, Lawson T, Jiang H.
europepmc   +1 more source

Crucial parameters for precise copy number variation detection in formalin‐fixed paraffin‐embedded solid cancer samples

Molecular Oncology, EarlyView.
This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.
Hanne Goris, Vasiliki Siozopoulou, Léon C van Kempen, Anne Sieben, Ella Roelant, Stig Hellemans, Elyne Backx, Laure Sorber, Koen De Winne, Senada Koljenović, Karen Zwaenepoel   +10 more
wiley   +1 more source

Global, Regional, and National Prevalence for Type 2 Diabetes Among Women of Childbearing Age, 1992-2021: An Age-Period-Cohort Analysis Based on the Global Burden of Disease Study 2021. [PDF]

J Diabetes Res
Xu Z, Liu M, Chen M, Shen X, Hao X, Yun Q, Zheng Y, Cui Y, Qiao J, Wang F.   +9 more
europepmc   +1 more source

Forecasting Adoption Trends for Adaptive Management of Conservation Scaling

Matt Clark, Thomas Pienkowski, Arundhati Jagadish, Carla L. Archibald, Stefan Gelcich, Hugh Govan, Robin Naidoo, Cristina Romero‐de‐Diego, Rebecca Weeks, Morena Mills   +9 more
openalex   +1 more source

Union Membership Trends: 2007 [PDF]

, 2008
McCarthy, Michael A.
core   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

INTERNET MARKETING TRENDS 2016 [PDF]

, 2016
Bas, N., Makukha, Yu.
core  

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

CMIP6 models cannot capture long-term forced changes in the tropical Pacific sea surface temperature gradient. [PDF]

Nat Commun
Byrne H, Seager R, Smerdon JE.
europepmc   +1 more source